Not a healthcare professional? Visit our Public site

This site May contain promotional material

Report adverse event

Menu

Close

1

Basket

User logged in

Overlay Text

For Healthcare Professionals registered in Ireland

May contain promotional material

Registration successful

You now have successfully registered for the event and for an account on this website.

In case you would like to receive SMS-reminders for the event you have registered, please scroll down to provide your mobile number.

Account activated – pending validation.

Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.

In the meantime, you can enjoy access to all the latest news, events and resources on our website

Registration completed – pending validation

Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up to 10 days.

In the meantime, you can continue to access all the unlocked content on this website.

Account activated - pending validation.

Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result. Please note this could take up to 10 days.

In the meantime, you can continue to access the unlocked content of the website.

Registration completed - pending validation.

Your account has been activated successfully, but we still need to validate you as a Healthcare Professional registered in Ireland. We’ll send you an email with the result of the validation process. Please note this could take up 10 days.

In the meantime, you can continue to access all the unlocked content on this website.

In case you would like to receive sms-reminders for the event you have registered, please update your communication preferences here.

already registered

X »

Anoro Ellipta 20 mcg

has been added to your basket

View Basket

Popup

ASYEVE0001=Event Registration-Portal
ASYEVE0002=Watched General Video
ASYEVE0003=Watched Virtual Rep Video
ASYEVE0004=Watched Patient Video
ASYEVE0005=Watched Expert Video
ASYEVE0006=Watched Webcast
ASYEVE0007=Downloaded Content-Portal
ASYEVE0008=Clicked to App Store
ASYEVE0009=Watched Learning Module Video
ASYEVE0010=eMail Sent
ASYEVE0011=eMail Read
ASYEVE0012=eMail Clicked
ASYEVE0013=Shared a Link
ASYEVE0014=Rep Request
ASYEVE0015=Joined health.gsk
ASYEVE0016=email Not Sent
ASYEVE0017=Email Not Sent
ASYEVE0018=Email Not Sent
ASYEVE0037=IJSFAID is not available
ASYEVE0038=EMAIL ID and IJSFAID is not available
ASYEVE0039=The user is opted out
ASYEVE0040=Scope IDs are different

ASYEVE0001=Event Registration-Portal
ASYEVE0002=Watched General Video
ASYEVE0003=Watched Virtual Rep Video
ASYEVE0004=Watched Patient Video
ASYEVE0005=Watched Expert Video
ASYEVE0006=Watched Webcast
ASYEVE0007=Downloaded Content-Portal
ASYEVE0008=Clicked to App Store
ASYEVE0009=Watched Learning Module Video
ASYEVE0010=eMail Sent
ASYEVE0011=eMail Read
ASYEVE0012=eMail Clicked
ASYEVE0013=Shared a Link
ASYEVE0014=Rep Request
ASYEVE0015=Joined health.gsk
ASYEVE0016=email Not Sent
ASYEVE0017=Email Not Sent
ASYEVE0018=Email Not Sent
ASYEVE0037=IJSFAID is not available
ASYEVE0038=EMAIL ID and IJSFAID is not available
ASYEVE0039=The user is opted out
ASYEVE0040=Scope IDs are different

Combodart

0.5mg dutasteride / 0.4mg tamsulosin hydrochloride

Summary of product characteristics

Patient information leaflet

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Product Overview

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Combodart Indications

ELITE Webcast

DRUG-DISEASE MODELLING:

The impact of early vs delayed initiation of combination therapy for BPH medical management

Watch expert discussion on clinical management now.

Catch up now

Clinical Data

Review recent clinical data on the domains of sexual function affected by Combodart, the 4 year CombAT study and the CONDUCT study on symptom relief.

Review data

PSA Monitoring

Read guideance regarding PSA monitoring in patients taking Combodart

PSA Monitoring

Indications

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Combodart Indications

Patient Resources

Download and view patient resources including IPSS cards, BPH Patient information and Combodart spesific leaflets

Download Resources

Efficacy

Learn how dutasteride and tamsulosin work together to manage moderate to severe BPH

Efficacy

Safety

Read key safety data including adverse events, contraindications and more

Safety

Dosage

Details on Combodart dosage and Administration.

Dosage

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Combodart is a registered trademark of the GlaxoSmithKline group of companies

Get in touch

To discuss our products, supply, educational events or any other information

Contact us

Registered in Ireland: GlaxoSmithKline (Ireland) Limited, a private company limited by shares, and a member of the GlaxoSmithKline group of companies. Registered in Ireland with Company Number 15513.
Registered office: 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.

CS. Last Updated: March 2021. PM-IE-NA-WCNT-210012

Sorry, this site is not supported on Android v4.3 and below.

Please update your operating system or use a different device.